Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4753928 | 0.85 | ELANE (0.50) | ELANEF2PLAUACHE | |
| SCHEMBL5109043 | 0.82 | ELANE (0.48) | ELANEF2PLAUACHE | |
| SCHEMBL9467082 | 0.82 | ELANE (0.48) | ELANEF2PLAUACHE | |
| SCHEMBL5120296 | 0.82 | ELANE (0.56) | ELANEF2PLAU | |
| SCHEMBL5120293 | 0.82 | ELANE (0.56) | ELANEF2PLAU | |
| SCHEMBL23782714 | 0.81 | ELANE (0.49) | ELANEF2PLAUACHE | |
| SCHEMBL2356995 | 0.81 | TYRO3 (0.46) | ELANE | |
| SCHEMBL19210227 | 0.81 | ELANE (0.50) | ELANE | |
| SCHEMBL2300687 | 0.81 | ELANE (0.53) | ELANE | |
| SCHEMBL517483 | 0.81 | ELANE (0.55) | ELANEF2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3648753-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2020-05-13 | — | — | EP | disclosed |
| CN-111093645-A | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| WO-2019010295-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2019-01-10 | — | — | WO | disclosed |
| WO-2011039388-A2 | 3-INDAZOLYL ETHER FAMILY WITH CANNABINOID AND/OR CHOLINERGIC PROPERTIES | UNIVERSIDAD REY JUAN CARLOS (ES) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | ELANE 1037/4885F2 2169/4885PLAU 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.